Skip to main content
. Author manuscript; available in PMC: 2024 Jul 1.
Published in final edited form as: Clin Gastroenterol Hepatol. 2023 Mar 25;21(8):2100–2109. doi: 10.1016/j.cgh.2023.03.019

Figure 1.

Figure 1.

The presence of clinically-significant portal hypertension (CSPH, determined noninvasively) establishes the indication for carvedilol with the goal of preventing cirrhosis decompensation. cACLD= compensated advanced chronic liver disease (noninvasive surrogate of compensated cirrhosis); LS = liver stiffness; PLT= platelet count; EVL= endoscopic variceal ligation. *Patients with LS <20 kPa and PLT >150,000/mm3 can circumvent endoscopy because the risk of having high-risk varices is minimal